NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
Clinical Trials
8 trialsNCT02943473 2020-12-16
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01248455 2019-11-19
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00983346 2016-07-11
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Phase 2 Terminated
NCT00942422 2015-03-27
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02353572 2015-03-09
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
Phase 1/2 Terminated
NCT01302366 2015-02-12
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00899353 2013-12-12
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Marshall University
Phase 2 Terminated